LG100268 NEW

Price	Get Latest Price
Package	1removed

Supply Ability:	10g
Update Time:	2026-05-11

Product Details

Product Name: LG100268	CAS No.: 153559-76-3
Purity: 99.83%	Supply Ability: 10g
Release date: 2026/05/11

Product Introduction

Bioactivity

Name	LG100268
Description	LG100268 is a potent, selective, and orally active retinoid X receptor (RXR) agonist that agonizes RXR-α, RXR-β, and RXR-γ at the nanomolar level, selectively exceeding the RAR by three orders of magnitude.LG100268 is capable of inducing transcriptional activation in adipocytes; affecting the RXRs and their chaperone receptor, Foxl2/Dmrt1, to induce flounder masculinization in juvenile flounder; inhibits keratin 17 expression in nigrostriatal epithelial cells; and increases PD-L1 expression in HER2 or triple-negative breast cancer.
In vitro	Methods: RAW264.7 cells were treated with LG100268 (100 nM-1 μM, 24 hours) and protein level changes were detected by WB. Results: LG100268 can downregulate CSF3 in RAW264.7 cells and reduce CXCL2 and IL-1β mRNA expression by 2.5 times. [6]
In vivo	Methods: To prevent invasive breast cancer, MMTV-erbB2 mice were treated chronically with vehicle, LG100268 (10 mg/kg), or LG100268 (100 mg/kg) by gavage starting at 3 months of age. For pre-invasive lesion studies, mice were treated with vehicle or LG100268 (100 mg/kg) by daily gavage for 4 months. Results: Chronic LG100268 treatment significantly prevented the development of invasive breast tumors. The median time to tumor development (age) was delayed from 217 days in the vehicle group to 357 days in the low-dose group. In the high-dose group, only 2 of 20 mice developed tumors after 430 days of treatment. [5]
Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 4 mg/mL (11 mM), Sonication is recommended.
Keywords	LG100268 \| LG 100268
Inhibitors Related	Stavudine \| Aceglutamide \| Hemin \| Tamoxifen \| Cysteamine hydrochloride \| Guanidine hydrochloride \| Hydroxychloroquine \| Enzalutamide \| Paeonol \| Naringin \| Alginic acid \| Sildenafil citrate
Related Compound Libraries	Bioactive Compound Library \| Multi-Target Compound Library \| Immunology/Inflammation Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.